SCHEMBL2930737

SCHEMBL2930737

NC(=O)c1n[nH]c2nc(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)c12

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.44
IKBKB O14920 1/20 0.41
CHUK O15111 1/20 0.41
CDC7 O00311 1/20 0.41
MAPK11 Q15759 5/20 0.41
KCNH2 Q12809 1/20 0.41
MAPK13 O15264 3/20 0.40
MAPK12 P53778 3/20 0.40
ALOX5 P09917 4/20 0.39
BTK Q06187 1/20 0.39
TGFBR1 P36897 1/20 0.39
GCGR P47871 1/20 0.39
KIT P10721 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384949 0.82 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL1385360 0.79 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12GCGR
SCHEMBL2930864 0.79 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12GCGR
SCHEMBL2931965 0.79 MAPK14 (0.47) MAPK14MAPK11MAPK13MAPK12GCGR
SCHEMBL2929817 0.79 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL1384634 0.76 ERBB2 (0.45) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL29652648 0.76 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL1386658 0.74 MAPK14 (0.53) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL4410117 0.73 MAPK14 (0.45) MAPK14MAPK11KCNH2MAPK13MAPK12
SCHEMBL1383795 0.72 MAPK11 (0.60) MAPK14MAPK11KCNH2MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885IKBKB 445/4885CHUK 74/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885IKBKB 489/4885CHUK 111/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885IKBKB 489/4885CHUK 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.